サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1733957

イブプロフェンの静脈内投与の世界市場

Intravenous Ibuprofen

出版日
ページ情報
英文 470 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.87円
イブプロフェンの静脈内投与の世界市場
出版日: 2025年05月23日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 470 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

イブプロフェンの静脈内投与の世界市場は2030年までに92億米ドルに達する見込み

2024年に67億米ドルと推定されるイブプロフェンの静脈内投与の世界市場は、2024年から2030年にかけてCAGR 5.4%で成長し、2030年には92億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである疼痛管理適応症は、CAGR 4.3%を記録し、分析期間終了時には46億米ドルに達すると予測されます。発熱治療薬セグメントは、分析期間中にCAGR 6.9%の成長が見込まれます。

米国市場は18億米ドルと推定、中国はCAGR 8.4％で成長予測

米国のイブプロフェンの静脈内投与市場は2024年に18億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに18億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは8.4%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.7%と5.3%と予測されています。欧州では、ドイツがCAGR約3.5%で成長すると予測されています。

世界のイブプロフェンの静脈内投与市場- 主要動向と促進要因のまとめ

なぜイブプロフェンの静脈内投与は急性疼痛管理に不可欠になりつつあるのか？

イブプロフェンの点滴静注は、その速効性、非オピオイド鎮痛・解熱特性により、臨床現場で広く認知されるようになってきており、中等度から重度の疼痛や発熱の管理に効果的な選択肢となっています。点滴で投与することにより、消化管をバイパスするため、経口NSAIDsと比較して、作用発現が速く、血漿中濃度が一定で、消化器系の副作用が軽減されます。特に患者が経口薬に耐えられない場合に、周術期疼痛プロトコール、救急部、集中治療室でよく使用されます。

特に術後の疼痛管理において、マルチモーダル鎮痛が重視されるようになっていることが、イブプロフェンの静脈内投与が採用された主な要因です。アセトアミノフェンや局所麻酔と併用することで相乗効果が得られることから、病院ではオピオイド温存戦略の基礎的要素としてイブプロフェンを取り入れるケースが増えています。さらに、解熱作用があることから、小児や術後患者など、経口摂取に耐えられない発熱患者への介入としても好まれています。イブプロフェンの静脈内投与の臨床的有用性は、外科手術にとどまらず、外傷、整形外科、腫瘍学、救命救急などへと拡大し続けています。

点滴イブプロフェンの製剤、安全性、臨床使用は、どのような進歩によって向上しているのでしょうか？

現在進行中の医薬品技術革新により、製剤の安全性、有効性、利便性が向上しています。最近の動向は、点滴時間の短縮、薬物の溶解性の向上、注射部位の刺激リスクの低減に重点を置いています。より良好な忍容性、輸液との適合性、および患者グループ間でのより広い適用性を確保するために、安定したpHプロファイルおよび強化された可溶化剤を有する製剤が導入されています。輸液時間を最適化する努力は、現在では5～10分という短いものもあり、高度急性期医療での迅速な実施を支えています。

臨床現場では、成人および小児患者向けの投与プロトコールが改良され、いくつかの地域で規制当局の承認が拡大されています。イブプロフェンの静脈内投与は、オピオイドへの依存を減らし、回復を促進し、入院期間を短縮する役割を果たすことから、術後回復促進（ERAS）プロトコールに含まれることが増えています。さらに、薬物動態プロファイリングと安全性データの改善により、投与ガイドラインに注意深く従えば、高齢者や軽度の腎機能障害患者を含むハイリスク集団において、イブプロフェンの静脈内投与は実行可能な選択肢となっています。

イブプロフェン静注の普及を牽引している臨床領域と世界市場は？

病院、外来手術センター、救急医療現場は、特に腹部手術、整形外科的外傷、婦人科的処置、歯科手術に伴う疼痛管理に使用され、依然としてイブプロフェンの静脈内投与の主要なエンドユーザーです。また、小児外科手術や発熱コントロールにも使用されるようになり、小児科専門施設での存在感が高まっています。麻酔科医や疼痛管理の専門家は、オピオイド最小化イニシアチブの一環として、イブプロフェンの静脈内投与を周術期治療のプロトコールに組み込むことを提唱する主要な利害関係者です。

地理的には、北米が依然として最大市場であり、これは手術件数の多さ、先進的な病院インフラ、多剤併用による疼痛戦略に対する規制当局のサポートが背景にあります。欧州もまた、強力な公的ヘルスケアシステムと国の治療ガイドラインへのイブプロフェン静注の組み入れに支えられ、大きな導入国となっています。一方、アジア太平洋は、特に中国、インド、韓国などの国々で急速な成長を遂げており、外科治療へのアクセスの改善や日帰り手術の増加が需要を促進しています。ラテンアメリカや中東の一部では、疼痛治療の近代化の一環として、非ステロイド性抗炎症薬の静脈内投与が徐々に病院の処方箋に組み込まれつつあります。

イブプロフェンの静脈内投与市場の成長はいくつかの要因によって牽引されている...

迅速な疼痛や発熱のコントロールが不可欠な臨床環境において、即効性のある非オピオイド鎮痛薬への需要が高まっていることが背景にあります。特に外科手術の回復プロトコールでは、オピオイド依存を減らすことが世界的に推進されているため、イブプロフェンの静脈内投与は多剤併用鎮痛レジメンの好ましい構成要素となっています。安全性が向上し、注入時間が短縮され、小児に適した製剤が開発されたことで、年齢層や治療環境における臨床使用はさらに拡大しています。

世界の外科手術件数の増加と術後回復促進（ERAS）プロトコルの採用が、標準化された術後ケアの一環としてイブプロフェンの静脈内投与に対する病院の需要を促進しています。さらに、臨床医の間でイブプロフェンの鎮痛・解熱効果に対する認識が高まっていることも、幅広い採用を後押ししています。また、新興市場における病院調達システム、支援的な償還政策、規制当局の承認を通じての入手可能性の増大も、市場拡大に寄与しています。これらの要因が相まって、イブプロフェンの静脈内投与は現代の疼痛および発熱管理における信頼性が高く、効果的で汎用性の高いソリューションとして、継続的な成長と臨床への統合が確実なものとなっています。

セグメント

適応症（疼痛管理、発熱、その他の適応症）、強さ（100 Mg、200 Mg、400 Mg、800 Mg）、年齢層（小児科、成人）、流通チャネル（病院薬局、小売薬局、オンライン薬局）

調査対象企業の例（計41社を掲載）

  • AFT Pharmaceuticals
  • Al Nabeel International Ltd.
  • Alveda Pharmaceuticals Inc.
  • Aurobindo Pharma Ltd.
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • CSL Limited
  • Cumberland Pharmaceuticals Inc.
  • Dano Health Group
  • Fresenius Kabi AG
  • Germin MED
  • Grifols, S.A.
  • Harbin Gloria Pharmaceuticals Co., Ltd.
  • Hikma Pharmaceuticals PLC
  • Hospira, Inc.（a Pfizer company）
  • Hyloris Pharmaceuticals SA
  • Laboratorios Valmorca C.A.
  • Pharma Bavaria International GmbH
  • Recordati Rare Diseases Inc.
  • XGEN Pharmaceuticals DJB Inc.

関税影響係数

Global Industry Analystsは、本社国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

無料アップデート弊社のお客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。我々の16,491以上のレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP33983

Global Intravenous Ibuprofen Market to Reach US$9.2 Billion by 2030

The global market for Intravenous Ibuprofen estimated at US$6.7 Billion in the year 2024, is expected to reach US$9.2 Billion by 2030, growing at a CAGR of 5.4% over the analysis period 2024-2030. Pain Management Indication, one of the segments analyzed in the report, is expected to record a 4.3% CAGR and reach US$4.6 Billion by the end of the analysis period. Growth in the Fever Indication segment is estimated at 6.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.8 Billion While China is Forecast to Grow at 8.4% CAGR

The Intravenous Ibuprofen market in the U.S. is estimated at US$1.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.8 Billion by the year 2030 trailing a CAGR of 8.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 5.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.5% CAGR.

Global Intravenous Ibuprofen Market - Key Trends & Drivers Summarized

Why Is Intravenous Ibuprofen Becoming Increasingly Integral in Acute Pain Management?

Intravenous (IV) ibuprofen is gaining widespread recognition in clinical settings due to its fast-acting, non-opioid analgesic and antipyretic properties, making it an effective option for managing moderate to severe pain and fever. Administered via infusion, it bypasses the gastrointestinal tract, offering rapid onset of action, consistent plasma concentrations, and reduced gastrointestinal side effects compared to oral NSAIDs. It is commonly used in perioperative pain protocols, emergency departments, and intensive care units, especially when patients are unable to tolerate oral medications.

The growing emphasis on multimodal analgesia-particularly in post-surgical pain management-is a key driver of IV ibuprofen’s adoption. Hospitals are increasingly incorporating it as a foundational component in opioid-sparing strategies, given its synergistic effect when combined with acetaminophen and regional anesthesia. Moreover, its antipyretic effect makes it a preferred intervention for febrile patients who cannot tolerate oral intake, including pediatric and post-operative populations. The clinical utility of IV ibuprofen continues to expand beyond surgery into trauma, orthopedics, oncology, and critical care.

What Advancements Are Enhancing Formulation, Safety, and Clinical Use of IV Ibuprofen?

Ongoing pharmaceutical innovation is improving the safety, efficacy, and convenience of intravenous ibuprofen formulations. Recent developments focus on minimizing infusion time, improving drug solubility, and reducing the risk of injection-site irritation. Formulations with stable pH profiles and enhanced solubilizing agents have been introduced to ensure better tolerability, compatibility with infusion fluids, and broader applicability across patient groups. Efforts to optimize infusion times-some now as low as 5 to 10 minutes-support faster implementation in high-acuity care settings.

In clinical practice, dosing protocols have been refined for both adults and pediatric patients, backed by expanded regulatory approvals in several regions. IV ibuprofen is increasingly being included in Enhanced Recovery After Surgery (ERAS) protocols for its role in reducing opioid reliance, accelerating recovery, and decreasing length of hospital stay. Additionally, improved pharmacokinetic profiling and safety data have made IV ibuprofen a viable choice in high-risk populations, including the elderly and patients with mild renal impairment, provided dosing guidelines are carefully followed.

Which Clinical Areas and Global Markets Are Driving Uptake of IV Ibuprofen?

Hospitals, ambulatory surgical centers, and emergency care settings remain the primary end-users of intravenous ibuprofen, particularly for managing pain associated with abdominal surgery, orthopedic trauma, gynecological procedures, and dental surgery. The product’s growing use in pediatric surgery and fever control is also expanding its presence in specialized pediatric institutions. Anesthesiologists and pain management specialists are key stakeholders advocating for IV ibuprofen's incorporation into perioperative care protocols as part of opioid minimization initiatives.

Geographically, North America remains the largest market, driven by high surgical volumes, advanced hospital infrastructure, and regulatory support for multimodal pain strategies. Europe is also a significant adopter, supported by strong public healthcare systems and the inclusion of IV ibuprofen in national treatment guidelines. Meanwhile, Asia-Pacific is witnessing rapid growth, particularly in countries like China, India, and South Korea, where improving access to surgical care and the rise of day-care procedures are fueling demand. Latin America and parts of the Middle East are gradually integrating IV NSAIDs into hospital formularies as part of modernized pain care approaches.

The Growth in the Intravenous Ibuprofen Market Is Driven by Several Factors…

It is driven by the increasing demand for fast-acting, non-opioid analgesics in clinical environments where rapid pain and fever control is essential. The global push to reduce opioid dependency-especially in surgical recovery protocols-has elevated IV ibuprofen as a preferred component of multimodal analgesia regimens. Enhanced formulations with improved safety, shorter infusion times, and pediatric suitability are further expanding clinical use across age groups and therapeutic settings.

The rising number of surgical procedures globally, along with the adoption of Enhanced Recovery After Surgery (ERAS) protocols, is fueling hospital demand for IV ibuprofen as part of standardized post-operative care. Additionally, growing awareness among clinicians of its dual analgesic and antipyretic benefits is supporting broader adoption. Increased availability through hospital procurement systems, supportive reimbursement policies, and regulatory approvals in emerging markets are also contributing to market expansion. Collectively, these factors are ensuring the continued growth and clinical integration of intravenous ibuprofen as a reliable, effective, and versatile solution in modern pain and fever management.

SCOPE OF STUDY:

The report analyzes the Intravenous Ibuprofen market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Indication (Pain Management, Fever, Other Indications); Strength (100 Mg, 200 Mg, 400 Mg, 800 Mg); Age Group (Pediatrics, Adults); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

  • AFT Pharmaceuticals
  • Al Nabeel International Ltd.
  • Alveda Pharmaceuticals Inc.
  • Aurobindo Pharma Ltd.
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • CSL Limited
  • Cumberland Pharmaceuticals Inc.
  • Dano Health Group
  • Fresenius Kabi AG
  • Germin MED
  • Grifols, S.A.
  • Harbin Gloria Pharmaceuticals Co., Ltd.
  • Hikma Pharmaceuticals PLC
  • Hospira, Inc. (a Pfizer company)
  • Hyloris Pharmaceuticals SA
  • Laboratorios Valmorca C.A.
  • Pharma Bavaria International GmbH
  • Recordati Rare Diseases Inc.
  • XGEN Pharmaceuticals DJB Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Intravenous Ibuprofen - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Need for Fast-Acting Analgesics in Acute Care Settings Drives Demand for IV Ibuprofen
    • Growth in Surgical and Postoperative Pain Management Spurs Adoption in Hospital Pharmacies
    • Increased Clinical Preference for Non-Opioid Pain Management Strengthens Business Case for IV NSAIDs
    • Expansion of Enhanced Recovery After Surgery (ERAS) Protocols Accelerates Use of IV Ibuprofen in Perioperative Care
    • Faster Onset and Predictable Pharmacokinetics of IV Formulations Support Market Growth in Emergency Medicine
    • Regulatory Approvals and Label Expansion for Pediatric and Post-Surgical Use Widen Patient Access
    • Rising Burden of Trauma and Orthopedic Injuries Drives In-Hospital Demand for Intravenous Pain Relief
    • Growing Awareness of Opioid-Sparing Strategies Throws the Spotlight on IV Ibuprofen as a First-Line Agent
    • Increased ICU Admissions and Surgical Volumes Post-Pandemic Sustain Hospital Demand for Parenteral NSAIDs
    • Expansion of Day Surgery and Ambulatory Care Facilities Supports Use of Rapid-Relief Analgesic Options
    • Hospital Formularies and Group Purchasing Trends Shape Competitive Positioning of IV Ibuprofen Products
    • Emergence of Combination Therapy Protocols Encourages Co-Administration of IV Ibuprofen With Adjunct Analgesics
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Intravenous Ibuprofen Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Intravenous Ibuprofen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Intravenous Ibuprofen by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Pain Management by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Pain Management by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Pain Management by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Fever by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Fever by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Fever by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for 100 Mg by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for 100 Mg by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for 100 Mg by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for 200 Mg by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for 200 Mg by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for 200 Mg by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for 400 Mg by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for 400 Mg by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for 400 Mg by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for 800 Mg by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for 800 Mg by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for 800 Mg by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Pediatrics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Pediatrics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Pediatrics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Adults by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Adults by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Adults by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Intravenous Ibuprofen Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Intravenous Ibuprofen by Indication - Percentage Breakdown of Value Sales for Pain Management, Fever and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Intravenous Ibuprofen by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Intravenous Ibuprofen by Strength - Percentage Breakdown of Value Sales for 100 Mg, 200 Mg, 400 Mg and 800 Mg for the Years 2015, 2025 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Intravenous Ibuprofen by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: USA 15-Year Perspective for Intravenous Ibuprofen by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for Intravenous Ibuprofen by Indication - Percentage Breakdown of Value Sales for Pain Management, Fever and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Canada 15-Year Perspective for Intravenous Ibuprofen by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Canada 15-Year Perspective for Intravenous Ibuprofen by Strength - Percentage Breakdown of Value Sales for 100 Mg, 200 Mg, 400 Mg and 800 Mg for the Years 2015, 2025 & 2030
    • TABLE 62: Canada Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Canada Historic Review for Intravenous Ibuprofen by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Canada 15-Year Perspective for Intravenous Ibuprofen by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • JAPAN
    • Intravenous Ibuprofen Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Japan 15-Year Perspective for Intravenous Ibuprofen by Indication - Percentage Breakdown of Value Sales for Pain Management, Fever and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Japan 15-Year Perspective for Intravenous Ibuprofen by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 71: Japan Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Japan Historic Review for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Japan 15-Year Perspective for Intravenous Ibuprofen by Strength - Percentage Breakdown of Value Sales for 100 Mg, 200 Mg, 400 Mg and 800 Mg for the Years 2015, 2025 & 2030
    • TABLE 74: Japan Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Japan Historic Review for Intravenous Ibuprofen by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Japan 15-Year Perspective for Intravenous Ibuprofen by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • CHINA
    • Intravenous Ibuprofen Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 77: China Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: China Historic Review for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: China 15-Year Perspective for Intravenous Ibuprofen by Indication - Percentage Breakdown of Value Sales for Pain Management, Fever and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 80: China Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: China Historic Review for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: China 15-Year Perspective for Intravenous Ibuprofen by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 83: China Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: China Historic Review for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: China 15-Year Perspective for Intravenous Ibuprofen by Strength - Percentage Breakdown of Value Sales for 100 Mg, 200 Mg, 400 Mg and 800 Mg for the Years 2015, 2025 & 2030
    • TABLE 86: China Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: China Historic Review for Intravenous Ibuprofen by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: China 15-Year Perspective for Intravenous Ibuprofen by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • EUROPE
    • Intravenous Ibuprofen Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 89: Europe Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 90: Europe Historic Review for Intravenous Ibuprofen by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Europe 15-Year Perspective for Intravenous Ibuprofen by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 92: Europe Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Europe Historic Review for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Europe 15-Year Perspective for Intravenous Ibuprofen by Indication - Percentage Breakdown of Value Sales for Pain Management, Fever and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 95: Europe Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Europe 15-Year Perspective for Intravenous Ibuprofen by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 98: Europe Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Europe 15-Year Perspective for Intravenous Ibuprofen by Strength - Percentage Breakdown of Value Sales for 100 Mg, 200 Mg, 400 Mg and 800 Mg for the Years 2015, 2025 & 2030
    • TABLE 101: Europe Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Europe Historic Review for Intravenous Ibuprofen by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Europe 15-Year Perspective for Intravenous Ibuprofen by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • FRANCE
    • Intravenous Ibuprofen Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 104: France Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: France Historic Review for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: France 15-Year Perspective for Intravenous Ibuprofen by Indication - Percentage Breakdown of Value Sales for Pain Management, Fever and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 107: France Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: France Historic Review for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: France 15-Year Perspective for Intravenous Ibuprofen by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 110: France Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: France Historic Review for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: France 15-Year Perspective for Intravenous Ibuprofen by Strength - Percentage Breakdown of Value Sales for 100 Mg, 200 Mg, 400 Mg and 800 Mg for the Years 2015, 2025 & 2030
    • TABLE 113: France Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: France Historic Review for Intravenous Ibuprofen by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: France 15-Year Perspective for Intravenous Ibuprofen by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • GERMANY
    • Intravenous Ibuprofen Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 116: Germany Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Germany Historic Review for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Germany 15-Year Perspective for Intravenous Ibuprofen by Indication - Percentage Breakdown of Value Sales for Pain Management, Fever and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 119: Germany Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Germany Historic Review for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Germany 15-Year Perspective for Intravenous Ibuprofen by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 122: Germany Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Germany Historic Review for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Germany 15-Year Perspective for Intravenous Ibuprofen by Strength - Percentage Breakdown of Value Sales for 100 Mg, 200 Mg, 400 Mg and 800 Mg for the Years 2015, 2025 & 2030
    • TABLE 125: Germany Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Germany Historic Review for Intravenous Ibuprofen by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Germany 15-Year Perspective for Intravenous Ibuprofen by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 128: Italy Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Italy Historic Review for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Italy 15-Year Perspective for Intravenous Ibuprofen by Indication - Percentage Breakdown of Value Sales for Pain Management, Fever and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 131: Italy Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Italy Historic Review for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Italy 15-Year Perspective for Intravenous Ibuprofen by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 134: Italy Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Italy Historic Review for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Italy 15-Year Perspective for Intravenous Ibuprofen by Strength - Percentage Breakdown of Value Sales for 100 Mg, 200 Mg, 400 Mg and 800 Mg for the Years 2015, 2025 & 2030
    • TABLE 137: Italy Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Italy Historic Review for Intravenous Ibuprofen by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Italy 15-Year Perspective for Intravenous Ibuprofen by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Intravenous Ibuprofen Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 140: UK Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: UK Historic Review for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: UK 15-Year Perspective for Intravenous Ibuprofen by Indication - Percentage Breakdown of Value Sales for Pain Management, Fever and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 143: UK Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: UK Historic Review for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: UK 15-Year Perspective for Intravenous Ibuprofen by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 146: UK Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: UK Historic Review for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: UK 15-Year Perspective for Intravenous Ibuprofen by Strength - Percentage Breakdown of Value Sales for 100 Mg, 200 Mg, 400 Mg and 800 Mg for the Years 2015, 2025 & 2030
    • TABLE 149: UK Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: UK Historic Review for Intravenous Ibuprofen by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: UK 15-Year Perspective for Intravenous Ibuprofen by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 152: Spain Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Spain Historic Review for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Spain 15-Year Perspective for Intravenous Ibuprofen by Indication - Percentage Breakdown of Value Sales for Pain Management, Fever and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 155: Spain Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Spain Historic Review for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Spain 15-Year Perspective for Intravenous Ibuprofen by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 158: Spain Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Spain Historic Review for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Spain 15-Year Perspective for Intravenous Ibuprofen by Strength - Percentage Breakdown of Value Sales for 100 Mg, 200 Mg, 400 Mg and 800 Mg for the Years 2015, 2025 & 2030
    • TABLE 161: Spain Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Spain Historic Review for Intravenous Ibuprofen by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Spain 15-Year Perspective for Intravenous Ibuprofen by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 164: Russia Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Russia Historic Review for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Russia 15-Year Perspective for Intravenous Ibuprofen by Indication - Percentage Breakdown of Value Sales for Pain Management, Fever and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 167: Russia Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Russia Historic Review for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Russia 15-Year Perspective for Intravenous Ibuprofen by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 170: Russia Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Russia Historic Review for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Russia 15-Year Perspective for Intravenous Ibuprofen by Strength - Percentage Breakdown of Value Sales for 100 Mg, 200 Mg, 400 Mg and 800 Mg for the Years 2015, 2025 & 2030
    • TABLE 173: Russia Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Russia Historic Review for Intravenous Ibuprofen by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Russia 15-Year Perspective for Intravenous Ibuprofen by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 176: Rest of Europe Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Rest of Europe Historic Review for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Rest of Europe 15-Year Perspective for Intravenous Ibuprofen by Indication - Percentage Breakdown of Value Sales for Pain Management, Fever and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 179: Rest of Europe Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Europe Historic Review for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Rest of Europe 15-Year Perspective for Intravenous Ibuprofen by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Europe Historic Review for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Europe 15-Year Perspective for Intravenous Ibuprofen by Strength - Percentage Breakdown of Value Sales for 100 Mg, 200 Mg, 400 Mg and 800 Mg for the Years 2015, 2025 & 2030
    • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Europe Historic Review for Intravenous Ibuprofen by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Europe 15-Year Perspective for Intravenous Ibuprofen by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Intravenous Ibuprofen Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 188: Asia-Pacific Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 189: Asia-Pacific Historic Review for Intravenous Ibuprofen by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Asia-Pacific 15-Year Perspective for Intravenous Ibuprofen by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Asia-Pacific Historic Review for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Asia-Pacific 15-Year Perspective for Intravenous Ibuprofen by Indication - Percentage Breakdown of Value Sales for Pain Management, Fever and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Asia-Pacific Historic Review for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Asia-Pacific 15-Year Perspective for Intravenous Ibuprofen by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Asia-Pacific Historic Review for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Asia-Pacific 15-Year Perspective for Intravenous Ibuprofen by Strength - Percentage Breakdown of Value Sales for 100 Mg, 200 Mg, 400 Mg and 800 Mg for the Years 2015, 2025 & 2030
    • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Asia-Pacific Historic Review for Intravenous Ibuprofen by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Asia-Pacific 15-Year Perspective for Intravenous Ibuprofen by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Intravenous Ibuprofen Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 203: Australia Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Australia Historic Review for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Australia 15-Year Perspective for Intravenous Ibuprofen by Indication - Percentage Breakdown of Value Sales for Pain Management, Fever and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 206: Australia Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Australia Historic Review for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Australia 15-Year Perspective for Intravenous Ibuprofen by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 209: Australia Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Australia Historic Review for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Australia 15-Year Perspective for Intravenous Ibuprofen by Strength - Percentage Breakdown of Value Sales for 100 Mg, 200 Mg, 400 Mg and 800 Mg for the Years 2015, 2025 & 2030
    • TABLE 212: Australia Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Australia Historic Review for Intravenous Ibuprofen by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Australia 15-Year Perspective for Intravenous Ibuprofen by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • INDIA
    • Intravenous Ibuprofen Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 215: India Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: India Historic Review for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: India 15-Year Perspective for Intravenous Ibuprofen by Indication - Percentage Breakdown of Value Sales for Pain Management, Fever and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 218: India Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: India Historic Review for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: India 15-Year Perspective for Intravenous Ibuprofen by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 221: India Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: India Historic Review for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: India 15-Year Perspective for Intravenous Ibuprofen by Strength - Percentage Breakdown of Value Sales for 100 Mg, 200 Mg, 400 Mg and 800 Mg for the Years 2015, 2025 & 2030
    • TABLE 224: India Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: India Historic Review for Intravenous Ibuprofen by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: India 15-Year Perspective for Intravenous Ibuprofen by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 227: South Korea Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: South Korea Historic Review for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: South Korea 15-Year Perspective for Intravenous Ibuprofen by Indication - Percentage Breakdown of Value Sales for Pain Management, Fever and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 230: South Korea Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: South Korea Historic Review for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: South Korea 15-Year Perspective for Intravenous Ibuprofen by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 233: South Korea Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: South Korea Historic Review for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: South Korea 15-Year Perspective for Intravenous Ibuprofen by Strength - Percentage Breakdown of Value Sales for 100 Mg, 200 Mg, 400 Mg and 800 Mg for the Years 2015, 2025 & 2030
    • TABLE 236: South Korea Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: South Korea Historic Review for Intravenous Ibuprofen by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: South Korea 15-Year Perspective for Intravenous Ibuprofen by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 239: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Asia-Pacific Historic Review for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Asia-Pacific 15-Year Perspective for Intravenous Ibuprofen by Indication - Percentage Breakdown of Value Sales for Pain Management, Fever and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 242: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Asia-Pacific Historic Review for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Rest of Asia-Pacific 15-Year Perspective for Intravenous Ibuprofen by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Asia-Pacific Historic Review for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Rest of Asia-Pacific 15-Year Perspective for Intravenous Ibuprofen by Strength - Percentage Breakdown of Value Sales for 100 Mg, 200 Mg, 400 Mg and 800 Mg for the Years 2015, 2025 & 2030
    • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Rest of Asia-Pacific Historic Review for Intravenous Ibuprofen by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Rest of Asia-Pacific 15-Year Perspective for Intravenous Ibuprofen by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Intravenous Ibuprofen Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 251: Latin America Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 252: Latin America Historic Review for Intravenous Ibuprofen by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Latin America 15-Year Perspective for Intravenous Ibuprofen by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 254: Latin America Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Latin America Historic Review for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Latin America 15-Year Perspective for Intravenous Ibuprofen by Indication - Percentage Breakdown of Value Sales for Pain Management, Fever and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 257: Latin America Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Latin America Historic Review for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Latin America 15-Year Perspective for Intravenous Ibuprofen by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 260: Latin America Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Latin America Historic Review for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Latin America 15-Year Perspective for Intravenous Ibuprofen by Strength - Percentage Breakdown of Value Sales for 100 Mg, 200 Mg, 400 Mg and 800 Mg for the Years 2015, 2025 & 2030
    • TABLE 263: Latin America Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Latin America Historic Review for Intravenous Ibuprofen by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Latin America 15-Year Perspective for Intravenous Ibuprofen by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 266: Argentina Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Argentina Historic Review for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Argentina 15-Year Perspective for Intravenous Ibuprofen by Indication - Percentage Breakdown of Value Sales for Pain Management, Fever and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 269: Argentina Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Argentina Historic Review for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Argentina 15-Year Perspective for Intravenous Ibuprofen by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 272: Argentina Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Argentina Historic Review for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Argentina 15-Year Perspective for Intravenous Ibuprofen by Strength - Percentage Breakdown of Value Sales for 100 Mg, 200 Mg, 400 Mg and 800 Mg for the Years 2015, 2025 & 2030
    • TABLE 275: Argentina Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Argentina Historic Review for Intravenous Ibuprofen by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Argentina 15-Year Perspective for Intravenous Ibuprofen by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 278: Brazil Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Brazil Historic Review for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Brazil 15-Year Perspective for Intravenous Ibuprofen by Indication - Percentage Breakdown of Value Sales for Pain Management, Fever and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 281: Brazil Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Brazil Historic Review for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Brazil 15-Year Perspective for Intravenous Ibuprofen by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 284: Brazil Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Brazil Historic Review for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Brazil 15-Year Perspective for Intravenous Ibuprofen by Strength - Percentage Breakdown of Value Sales for 100 Mg, 200 Mg, 400 Mg and 800 Mg for the Years 2015, 2025 & 2030
    • TABLE 287: Brazil Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Brazil Historic Review for Intravenous Ibuprofen by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Brazil 15-Year Perspective for Intravenous Ibuprofen by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 290: Mexico Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Mexico Historic Review for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Mexico 15-Year Perspective for Intravenous Ibuprofen by Indication - Percentage Breakdown of Value Sales for Pain Management, Fever and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 293: Mexico Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Mexico Historic Review for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Mexico 15-Year Perspective for Intravenous Ibuprofen by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 296: Mexico Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Mexico Historic Review for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Mexico 15-Year Perspective for Intravenous Ibuprofen by Strength - Percentage Breakdown of Value Sales for 100 Mg, 200 Mg, 400 Mg and 800 Mg for the Years 2015, 2025 & 2030
    • TABLE 299: Mexico Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Mexico Historic Review for Intravenous Ibuprofen by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Mexico 15-Year Perspective for Intravenous Ibuprofen by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 302: Rest of Latin America Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Latin America Historic Review for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Rest of Latin America 15-Year Perspective for Intravenous Ibuprofen by Indication - Percentage Breakdown of Value Sales for Pain Management, Fever and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 305: Rest of Latin America Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Rest of Latin America Historic Review for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Rest of Latin America 15-Year Perspective for Intravenous Ibuprofen by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Rest of Latin America Historic Review for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 310: Rest of Latin America 15-Year Perspective for Intravenous Ibuprofen by Strength - Percentage Breakdown of Value Sales for 100 Mg, 200 Mg, 400 Mg and 800 Mg for the Years 2015, 2025 & 2030
    • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Rest of Latin America Historic Review for Intravenous Ibuprofen by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 313: Rest of Latin America 15-Year Perspective for Intravenous Ibuprofen by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Intravenous Ibuprofen Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 314: Middle East Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 315: Middle East Historic Review for Intravenous Ibuprofen by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 316: Middle East 15-Year Perspective for Intravenous Ibuprofen by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 317: Middle East Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Middle East Historic Review for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 319: Middle East 15-Year Perspective for Intravenous Ibuprofen by Indication - Percentage Breakdown of Value Sales for Pain Management, Fever and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 320: Middle East Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Middle East Historic Review for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 322: Middle East 15-Year Perspective for Intravenous Ibuprofen by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 323: Middle East Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Middle East Historic Review for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 325: Middle East 15-Year Perspective for Intravenous Ibuprofen by Strength - Percentage Breakdown of Value Sales for 100 Mg, 200 Mg, 400 Mg and 800 Mg for the Years 2015, 2025 & 2030
    • TABLE 326: Middle East Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Middle East Historic Review for Intravenous Ibuprofen by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 328: Middle East 15-Year Perspective for Intravenous Ibuprofen by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 329: Iran Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 330: Iran Historic Review for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 331: Iran 15-Year Perspective for Intravenous Ibuprofen by Indication - Percentage Breakdown of Value Sales for Pain Management, Fever and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 332: Iran Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 333: Iran Historic Review for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 334: Iran 15-Year Perspective for Intravenous Ibuprofen by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 335: Iran Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 336: Iran Historic Review for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 337: Iran 15-Year Perspective for Intravenous Ibuprofen by Strength - Percentage Breakdown of Value Sales for 100 Mg, 200 Mg, 400 Mg and 800 Mg for the Years 2015, 2025 & 2030
    • TABLE 338: Iran Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 339: Iran Historic Review for Intravenous Ibuprofen by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 340: Iran 15-Year Perspective for Intravenous Ibuprofen by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 341: Israel Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 342: Israel Historic Review for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 343: Israel 15-Year Perspective for Intravenous Ibuprofen by Indication - Percentage Breakdown of Value Sales for Pain Management, Fever and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 344: Israel Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 345: Israel Historic Review for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 346: Israel 15-Year Perspective for Intravenous Ibuprofen by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 347: Israel Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 348: Israel Historic Review for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 349: Israel 15-Year Perspective for Intravenous Ibuprofen by Strength - Percentage Breakdown of Value Sales for 100 Mg, 200 Mg, 400 Mg and 800 Mg for the Years 2015, 2025 & 2030
    • TABLE 350: Israel Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 351: Israel Historic Review for Intravenous Ibuprofen by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 352: Israel 15-Year Perspective for Intravenous Ibuprofen by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 353: Saudi Arabia Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 354: Saudi Arabia Historic Review for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 355: Saudi Arabia 15-Year Perspective for Intravenous Ibuprofen by Indication - Percentage Breakdown of Value Sales for Pain Management, Fever and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 356: Saudi Arabia Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 357: Saudi Arabia Historic Review for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 358: Saudi Arabia 15-Year Perspective for Intravenous Ibuprofen by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 360: Saudi Arabia Historic Review for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 361: Saudi Arabia 15-Year Perspective for Intravenous Ibuprofen by Strength - Percentage Breakdown of Value Sales for 100 Mg, 200 Mg, 400 Mg and 800 Mg for the Years 2015, 2025 & 2030
    • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 363: Saudi Arabia Historic Review for Intravenous Ibuprofen by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 364: Saudi Arabia 15-Year Perspective for Intravenous Ibuprofen by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 365: UAE Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 366: UAE Historic Review for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 367: UAE 15-Year Perspective for Intravenous Ibuprofen by Indication - Percentage Breakdown of Value Sales for Pain Management, Fever and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 368: UAE Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 369: UAE Historic Review for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 370: UAE 15-Year Perspective for Intravenous Ibuprofen by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 371: UAE Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 372: UAE Historic Review for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 373: UAE 15-Year Perspective for Intravenous Ibuprofen by Strength - Percentage Breakdown of Value Sales for 100 Mg, 200 Mg, 400 Mg and 800 Mg for the Years 2015, 2025 & 2030
    • TABLE 374: UAE Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 375: UAE Historic Review for Intravenous Ibuprofen by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 376: UAE 15-Year Perspective for Intravenous Ibuprofen by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 377: Rest of Middle East Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 378: Rest of Middle East Historic Review for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 379: Rest of Middle East 15-Year Perspective for Intravenous Ibuprofen by Indication - Percentage Breakdown of Value Sales for Pain Management, Fever and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 380: Rest of Middle East Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 381: Rest of Middle East Historic Review for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 382: Rest of Middle East 15-Year Perspective for Intravenous Ibuprofen by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 384: Rest of Middle East Historic Review for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 385: Rest of Middle East 15-Year Perspective for Intravenous Ibuprofen by Strength - Percentage Breakdown of Value Sales for 100 Mg, 200 Mg, 400 Mg and 800 Mg for the Years 2015, 2025 & 2030
    • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 387: Rest of Middle East Historic Review for Intravenous Ibuprofen by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 388: Rest of Middle East 15-Year Perspective for Intravenous Ibuprofen by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • AFRICA
    • Intravenous Ibuprofen Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 389: Africa Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 390: Africa Historic Review for Intravenous Ibuprofen by Indication - Pain Management, Fever and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 391: Africa 15-Year Perspective for Intravenous Ibuprofen by Indication - Percentage Breakdown of Value Sales for Pain Management, Fever and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 392: Africa Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 393: Africa Historic Review for Intravenous Ibuprofen by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 394: Africa 15-Year Perspective for Intravenous Ibuprofen by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 395: Africa Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 396: Africa Historic Review for Intravenous Ibuprofen by Strength - 100 Mg, 200 Mg, 400 Mg and 800 Mg Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 397: Africa 15-Year Perspective for Intravenous Ibuprofen by Strength - Percentage Breakdown of Value Sales for 100 Mg, 200 Mg, 400 Mg and 800 Mg for the Years 2015, 2025 & 2030
    • TABLE 398: Africa Recent Past, Current & Future Analysis for Intravenous Ibuprofen by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 399: Africa Historic Review for Intravenous Ibuprofen by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 400: Africa 15-Year Perspective for Intravenous Ibuprofen by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030

IV. COMPETITION